Clinicopathological Features and Prognosis of Patients Newly Diagnosed With Lung Adenocarcinoma With Both EGFR Mutation and C-MET Amplification.
10.3881/j.issn.1000-503X.15416
- Author:
Wan-Ling WANG
1
;
Cun-Bao XU
1
;
Jin-Ling YANG
1
;
Hong-Tu ZHANG
2
;
Yi-Feng CHEN
1
Author Information
1. Department of Pathology,Quanzhou First Hospital Affiliated to Fujian Medical University,Quanzhou,Fujian 362000,China.
2. Department of Pathology,National Cancer Center,National Clinical Research Center for Cancer,Cancer Hospital,CAMS and PUMC,Beijing 100021,China.
- Publication Type:Journal Article
- Keywords:
C-MET amplification;
EGFR gene;
lung adenocarcinoma
- MeSH:
Humans;
In Situ Hybridization, Fluorescence;
Retrospective Studies;
Prognosis;
Adenocarcinoma of Lung/genetics*;
Mutation;
Lung Neoplasms/genetics*;
ErbB Receptors/genetics*
- From:
Acta Academiae Medicinae Sinicae
2023;45(4):627-633
- CountryChina
- Language:Chinese
-
Abstract:
Objective To explore the clinicopathological features and prognosis of the patients newly diagnosed with lung adenocarcinoma with both EGFR mutation and C-MET amplification.Methods The pathological sections were reviewed.EGFR mutation was detected by amplification refractory mutation system-quantitative real-time polymerase chain reaction,and C-MET amplification by fluorescence in situ hybridization.The clinicopathological features and survival data of the patients newly diagnosed with lung adenocarcinoma with both EGFR mutation and C-MET amplification were analyzed retrospectively.Results In 11 cases of EGFR mutation combined with C-MET amplification,complex glands and solid high-grade components were observed under a microscope in 10 cases except for one case with a cell block,the tissue structure of which was difficult to be evaluated.The incidence of lung adenocarcinoma in the patients with EGFR mutation combined with C-MET amplification at clinical stage Ⅳ was higher than that in the EGFR mutation or C-MET amplification group (all P<0.001),whereas the difference was not statistically significant between the EGFR mutation group and C-MET amplification group at each clinical stage (all P>0.05).There was no significant difference in the trend of survival rate between EGFR gene group and C-MET amplification group (χ2=0.042,P=0.838),while the survival of the patients with EGFR mutation combined with C-MET amplification was worse than that of the patients with EGFR mutation (χ2=246.72,P<0.001) or C-MET amplification (χ2=236.41,P<0.001).Conclusions The patients newly diagnosed with lung adenocarcinoma with EGFR mutation plus C-MET amplification demonstrate poor histological differentiation,rapid progress,and poor prognosis.The patients are often in the advanced stage when being diagnosed with cancer.Attention should be paid to this concurrent adverse driving molecular event in clinical work.With increasing availability,the inhibitors targeting C-MET may serve as an option to benefit these patients in the near future.
